Skip to content

Discontinued — last reported Q2 '22

Operating margin at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-2,776.6%-820pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-543.9%-271pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
13.4%
Precigen logo
PrecigenPGEN
-2,890.9%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-12%-5.7pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-83.8%-3.0pp

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.7B+468%
Enterprise value$1.5B
P/S41.6×

Profitability

See full
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Calculated from Palvella Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Palvella Therapeutics’s 10-Q, filed August 4, 2022, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's operating margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's operating margin?
Palvella Therapeutics (PVLA) reported operating margin of -183.2% in Q2 2022.
How has Palvella Therapeutics's operating margin changed year-over-year?
Palvella Therapeutics's operating margin increased by 8.0% year-over-year, from -199% to -183.2%.
What does operating margin mean?
Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.